SNP information rs9934438

Research and publications:

  15358623   A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin.

  15883587   Common VKORC1 and GGCX polymorphisms associated with warfarin dose.

  16201835   A C1173T dimorphism in the VKORC1 gene determines coumarin sensitivity and bleeding risk.

  16270629   VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation.

  16432637   Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patients.

  16611750   Polymorphisms in the VKORC1 gene are strongly associated with warfarin dosage requirements in patients receiving anticoagulation.

  16676068   The influence of sequence variations in factor VII, gamma-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement.

  16815313   VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation.

  16821005   Multiple gene polymorphisms and warfarin sensitivity.

  17031720   1173C>T polymorphism in VKORC1 modulates the required warfarin dose.

  17048007   Association of warfarin dose with genes involved in its action and metabolism

  17111199   Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.

  17329985   Warfarin response and vitamin K epoxide reductase complex 1 in African Americans and Caucasians.

  17387222   Genetic-based dosing in orthopedic patients beginning warfarin therapy.

  17391071   Factors affecting the interindividual variability of warfarin dose requirement in adult Korean patients.

  17596133   The genetic interaction between VKORC1 c1173t and calumenin a29809g modulates the anticoagulant response of acenocoumarol.

  17989110   Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation.

  18030307   Combination of phenotype assessments and CYP2C9-VKORC1 polymorphisms in the determination of warfarin dose requirements in heavily medicated patients.

  18218987   Vitamin K epoxide reductase complex subunit 1 (VKORC1) polymorphism and aortic calcification: the Rotterdam Study.

  18240904   Ethnic differences in the VKORC1 gene polymorphism and an association with warfarin dosage requirements in cardiovascular surgery patients.

  18252229   Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations.

  18322281   Genetic determinants of response to warfarin during initial anticoagulation.

  18466099   Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans.

  18523153   Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement.

  18559094   Warfarin dose and INR related to genotypes of CYP2C9 and VKORC1 in patients with myocardial infarction.

  18596683   Dosing algorithms to predict warfarin maintenance dose in Caucasians and African Americans

  18680736   Genetic factors contribute to patient-specific warfarin dose for Han Chinese.

  18752379   Warfarin pharmacogenetics.

  18781852   Effects of CYP2C9 and VKORC1 on INR variations and dose requirements during initial phase of anticoagulant therapy.

  18809808   Ethnic differences in cardiovascular drug response: potential contribution of pharmacogenetics.

  18813101   Impact of VKORC1 haplotypes on long-term graft function in kidney transplantation.

  18855533   VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans.

  19074728   Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy.

  19077919   Effect of CYP2C9 and VKORC1 genotypes on early-phase and steady-state warfarin dosing in Korean patients with mechanical heart valve replacement.

  19172700   A genotyping method for VKORC1 1173C > T by Pyrosequencing technology.

  19177029   Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients.

  19225451   Genotypes associated with reduced activity of VKORC1 and CYP2C9 and their modification of acenocoumarol anticoagulation during the initial treatment period.

  19228618   Estimation of the warfarin dose with clinical and pharmacogenetic data.

  19270263   Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy.

  19297219   Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy.

  19300499   A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose.

  19940803   VKORC1 pharmacogenomics summary.

  19955245   Warfarin sensitivity genotyping: a review of the literature and summary of patient experience.

  20020283   Genetic determinants of acenocoumarol and phenprocoumon maintenance dose requirements.

  20128861   Comparative performance of gene-based warfarin dosing algorithms in a multiethnic population.

  20203262   Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups.

  20375999   Integration of genetic, clinical, and INR data to refine warfarin dosing.

  20585445   A novel, single algorithm approach to predict acenocoumarol dose based on CYP2C9 and VKORC1 allele variants.

  20585834   Warfarin dosing algorithm using clinical, demographic and pharmacogenetic data from Chinese patients.

  20709439   Warfarin dosing in patients with impaired kidney function.

  20716240   New genetic variant that might improve warfarin dose prediction in African Americans.

  20733952   Warfarin genotyping using three different platforms.

  20921971   Mapping genes that predict treatment outcome in admixed populations.

  21127708   Genetic variation of VKORC1 and CYP4F2 genes related to warfarin maintenance dose in patients with myocardial infarction.

  21176721   Contribution of 1173C > T polymorphism in the VKORC1 gene to warfarin dose requirements in Han Chinese patients receiving anticoagulation.

  21179214   VKORC1 pharmacogenetics and pharmacoproteomics in patients on warfarin anticoagulant therapy: transthyretin precursor as a potential biomarker.

  21179439   VKORC1 common variation and bone mineral density in the Third National Health and Nutrition Examination Survey.

  21219403   Amoxicillin/clavulanic acid-warfarin drug interaction: a randomized controlled trial.

  21270790   The missing association: sequencing-based discovery of novel SNPs in VKORC1 and CYP2C9 that affect warfarin dose in African Americans.

  21273734   Effect of the VKORC1 genotype on warfarin dose requirements in Japanese pediatric patients.

  21320153   Influence of genetic, biological and pharmacological factors on warfarin dose in a Southern Brazilian population of European ancestry.

  21326313   Proposal of pharmacogenetics-based warfarin dosing algorithm in Korean patients.

  21450715   High-dimensional pharmacogenetic prediction of a continuous trait using machine learning techniques with application to warfarin dose prediction in African Americans.

  21562135   Absence of novel CYP4F2 and VKORC1 coding region DNA variants in patients requiring high warfarin doses.

  21639946   Genetic factors associated with patient-specific warfarin dose in ethnic Indonesians.

  21672908   Facilitating pharmacogenetic studies using electronic health records and natural-language processing: a case study of warfarin.

  21883387   Impact of genetic factors (VKORC1, CYP2C9, CYP4F2 and EPHX1) on the anticoagulation response to fluindione.

  21921273   Cardiovascular pharmacogenomics.

  21935354   Phased whole-genome genetic risk in a family quartet using a major allele reference sequence.

  21981797   Development and comparison of a warfarin-dosing algorithm for Korean patients with atrial fibrillation.

  22023024   The pharmacogenetics of the response to warfarin in Chinese.

  22075505   The effect of CYP2C9, VKORC1 genotypes and old age on warfarin pharmacologic sensitivity in korean patients with thromboembolic disease.

  22118051   Genetic variants in CYP (-1A2, -2C9, -2C19, -3A4 and -3A5), VKORC1 and ABCB1 genes in a black South African population: a window into diversity.

  22122181   Role of pharmacogenomics in the management of traditional and novel oral anticoagulants.

  22186998   Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy.

  22248286   Genetic polymorphisms are associated with variations in warfarin maintenance dose in Han Chinese patients with venous thromboembolism.

  22329724   Predicting warfarin dosage in European-Americans and African-Americans using DNA samples linked to an electronic health record.

  22534826   A new algorithm to predict warfarin dose from polymorphisms of CYP4F2 , CYP2C9 and VKORC1 and clinical variables: derivation in Han Chinese patients with non valvular atrial fibrillation.

  22549502   Effects of CYP4F2 gene polymorphisms on warfarin clearance and sensitivity in Korean patients with mechanical cardiac valves.

  22563365   Pharmacogenomic Research in South Africa: Lessons Learned and Future Opportunities in the Rainbow Nation.

  22676711   Pharmacogenomics of warfarin in populations of African descent.

  22920394   Validation of the acenocoumarol EU-PACT algorithms: similar performance in the Rotterdam Study cohort as in the original study.

  22952875   Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis.

  22992668   Pharmacogenomics knowledge for personalized medicine.

  23016735   Personalized approach of medication by indirect anticoagulants tailored to the patient-Russian context: what are the prospects?

  23124848   Brief Report: Single-nucleotide polymorphisms in VKORC1 are risk factors for systemic lupus erythematosus in Asians.

  23159229   The influence of VKORC1 and CYP2C9 gene sequence variants on the stability of maintenance phase warfarin treatment.

  23183958   Genetic and clinical determinants influencing warfarin dosing in children with heart disease.

  23285254   Positive selection in the chromosome 16 VKORC1 genomic region has contributed to the variability of anticoagulant response in humans.

  23300409   Chapter 7: Pharmacogenomics.

  23691226   Novel associations of VKORC1 variants with higher acenocoumarol requirements.

  23797323   Pharmacogenomics of anti-platelet and anti-coagulation therapy.

  23990957   Warfarin anticoagulant therapy: a Southern Italy pharmacogenetics-based dosing model.

  24019055   Effect of CYP2C9, VKORC1, CYP4F2 and GGCX genetic variants on warfarin maintenance dose and explicating a new pharmacogenetic algorithm in South Indian population.

  24503627   Genetic risk factors for major bleeding in patients treated with warfarin in a community setting.

  24602049   Association of gene polymorphisms with the risk of warfarin bleeding complications at therapeutic INR in patients with mechanical cardiac valves.

  24728385   Verification of pharmacogenetics-based warfarin dosing algorithms in Han-Chinese patients undertaking mechanic heart valve replacement.

  24944790   Screening for 392 polymorphisms in 141 pharmacogenes.

  24966969   High resolution melting method to detect single nucleotide polymorphism of VKORC1 and CYP2C9.